|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Unverricht-Lundborg Syndrome | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Epilepsies, Myoclonic | |||||
| Epilepsy | |||||
| Myoclonic Epilepsies, Progressive | |||||
| Syndrome | |||||
| 3 | More general conditions related to this trial | ||||
| Brain Diseases | |||||
| Central Nervous System Diseases | |||||
| Disease | |||||
| Genetic Diseases, Inborn | |||||
| Heredodegenerative Disorders, Nervous System | |||||
| Nervous System Diseases | |||||
| Neurodegenerative Diseases | |||||
| Pathologic Processes | |||||
| 4 | Interventions listed in this trial | ||||
| Ropinirole | |||||
| 5 | More general drug interventions related to this trial | ||||
| Anti-Dyskinesia Agents | |||||
| Antiparkinson Agents | |||||
| Central Nervous System Agents | |||||
| Dopamine Agents | |||||
| Dopamine Agonists | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| University of Turku | |||||